Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

57 results about "Opalescence" patented technology

Opalescence refers to the optical phenomena displayed by the mineraloid gemstone opal (hydrated silicon dioxide). However, there are three notable types of opal (precious, common, and fire), each with different optical effects, so the intended meaning varies depending on context. The optical effects seen in various types of opal are a result of refraction (precious and fire) or reflection (common) due to the layering, spacing, and size of the myriad microscopic silicon dioxide spheres and included water (or air) in its physical structure. When the size and spacing of the silica spheres are relatively small, refracted blue-green colors are prevalent; when relatively larger, refracted yellow-orange-red colors are seen; and when larger yet, reflection yields a milky-hazy sheen.

Ropivacaine nano particle, preparation method thereof and optimizing experimental method of effect of the ropivacaine nano particle

The invention relates to the field of preparation of medicines and particularly relates to ropivacaine nano particles, a preparation method thereof and an optimizing experimental method of effects of the ropivacaine nano particles. The preparation method comprises following steps: (A) dissolving ropivacaine free alkali and polylactic acid-polyglycollic acid segmented copolymer in dichloromethane to form an organic phase while a polyvinyl alcohol solution is employed as an aqueous phase; (B) performing evaporation to a white emulsion at 30-40 DEG C to remove the organic phase to obtain a pale blue opalescence suspension liquid; and (C) performing centrifugal separation to the pale blue opalescence suspension liquid to obtain a precipitate, washing the precipitate, and performing ultrasonic dispersion and a vacuum freeze-drying process to obtain the ropivacaine nano particles. By means of the prepration method of the ropivacaine nano particles, an in-vitro releasing research proves that the ropivacaine nano particles has a releasing rate being about 73% in 96 h, a slow-releasing effect is quite good and a pain-relieving requirement on acute pains, such as post-operation pain and the like, can be satisfied just through one-time dosing.
Owner:FUZHOU GENERAL HOSPITAL OF NANJING MILITARY COMMAND P L A

Hydroxytyrosol containing nanoemulsion preparation and preparation method of lyophilized agent thereof

InactiveCN108888595AImprove stabilitySolve the shortcomings of poor stabilityCosmetic preparationsPowder deliveryWater bathsHydroxytyrosol
The invention discloses a hydroxytyrosol containing nanoemulsion preparation and a lyophilized agent thereof. The hydroxytyrosol containing nanoemulsion preparation is prepared from hydroxytyrosol, asurface active agent, an oil phase and a water phase. A preparation method of the hydroxytyrosol containing nanoemulsion preparation comprises the steps that 1, the surface active agent and hydroxytyrosol are weighed and added into oil to serve as the oil phase, and the materials are stirred and mixed in a water bath; 2, purified water is weighed and added into a beaker, the materials are placed in the water bath, the oil phase is slowly and dropwise added into the water bath under the water bath condition, and the materials are fully stirred to be completely emulsified until and a clear transparent solution with bluish opalescence and with the viscosity similar to an aqueous solution is formed; 3, the nanoemulsion preparation is frozen and dried, water is removed, and the hydroxytyrosol nanoemulsion freeze-dried preparation is prepared. The hydroxytyrosol nanoemulsion prepared through the method has the advantages of being good in stability, low in viscosity, small in grain size and capable of being diffused and permeating into the skin more easily, the lyophilized preparation is conveneitn to store and transport, and can be added into cosmetics, medicine and healthcare food moreflexibly and conveniently.
Owner:SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES

Method for preparing gemcitabine hydrochloride lyophilized powder

The invention relates to the field of pharmaceutic preparations and discloses a method for preparing gemcitabine hydrochloride lyophilized powder. According to the method for preparing the gemcitabine hydrochloride lyophilized powder, a primary pre-freezing process and a stage drying process are used for lyophilization; appropriate vacuum degrees and temperature are matched at all drying stages to avoid the problem that hydrochloric acid is removed from gemcitabine hydrochloride under high vacuum degree, and drying efficiency is low due to low vacuum degree; meanwhile, temperature is slowly raised at different speed at different drying stages, and the problem that the gemcitabine hydrochloride is deacidified due to too high heating speed can be solved. Compared with the prior art, the method for preparing the gemcitabine hydrochloride lyophilized powder has the advantages that the method is easy to operate, lyophilization time is short, and drying temperature is low; the prepared gemcitabine hydrochloride lyophilized powder product is high in outer structural quality and redissolution performance; a redissolution solution is clear and transparent, and opalescence is avoided; relative substances are low in content, and the prepared gemcitabine hydrochloride lyophilized powder is safe and reliable in quality; and the method is suitable for preparing the gemcitabine hydrochloridelyophilized powder and can be widely applied to large-scale production of the gemcitabine hydrochloride lyophilized powder.
Owner:CHONGQING LUMMY PHARMA

Camptothecinum derivative emulsion agent and preparation thereof

The invention provides an emulsion of camptothecin derivative which comprises the components by weight: 0.01 to 0.1 percent of 10-methyl-9 nitryl camptothecin, 5 to 20 percent of oil for injection, 1-4 percent of emulsifier, 1-4 percent of co-emulsifier, 0 to 60 percent of solubilizer, 2 to 3 percent of glycerin of isotonizing agent and Vitamin E and the rest is water for injection; the sum of the percentages of all components is 100 percent. The emulsifier and a co-surfactant are dissolved in the oil for injection, heated and added with the solubilizer and 10-methyl-9 nitryl camptothecin to be dissolved, ant then added with the glycerin of isotonizing agent and the water for injection and made into primary emulsion by means of high speed homogenization or ultrasound, then further made into the emulsion by means of high pressure homogenization or micro jet. The prepared emulsion of the invention has uniform particle diameter and high content of drug and the appearance of the emulsion is a milky white or blue opalescence homogeneous system; meanwhile, compared with other preparation methods, the micro jet technique is adopted by the invention to prepare the emulsion, so as to ensure less loss of drug and better stability of the emulsion. The emulsion of camptothecin derivative of the invention has reasonable design and easy operation, which is suitable for practical use.
Owner:ZHEJIANG UNIV

Method for preparing interleukin-11 semi-finished product solution, and products thereof

The invention discloses a method for preparing an interleukin-11 semi-finished product solution, and products thereof. The method comprises the following steps of: dissolving interleukin-11 into a phosphate buffer, adding glycin, and stirring to obtain the mixed solution; adjusting the pH value of the mixed solution; supplementing injection water to fix volume, and stirring to obtain the interleukin-11 semi-finished product solution, wherein the pH value of the mixed solution is adjusted to 8.0-9.5 by using diluted alkaline or is adjusted to 1.0-6.0 by using diluted acid. The method better solves the problems of accumulation and settlement of the interleukin-11 in the preparing, sterile filtering and packaging processes of the semi-finished product. The prepared semi-finished product solution is clear and transparent, and has no opalescence, and the volume of the protein of the main drug is accurately fixed. The sterile filtration of the prepared semi-finished product solution semi-finished product solution is easy to implement, the filter membrane can not be blocked, and the accumulation and settlement can not be caused during the packaging process of the semi-finished product. The clearness of the finished product is good after redissolution, no flocky precipitate or opalescence can be produced, the stable activity is maintained, and the use quantity is reduced in clinic.
Owner:EAST CHINA UNIV OF SCI & TECH +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products